Business Model

DNDi’s primary objective is to deliver 11 to 13 new treatments by 2018
(five to seven more than the six already in implementation phase in
2011) for leishmaniasis, human African trypanosomiasis (sleeping
sickness), Chagas disease, malaria, paediatric HIV, and specific
helminth infections and to establish a strong R&D portfolio that
addresses patients’ treatment needs and supports long term objectives.

Highlights of the Business Plan

Although the R&D landscape for neglected tropical diseases (NTDs) has improved from 2000, sustainable public funding remains a critical issue to support these R&D efforts.

DNDi will concentrate its efforts on the three primary diseases (leishmaniasis, Chagas disease, and human African trypanosomiasis). It will complete its malaria activities and launch two ‘mini-portfolios’: paediatric HIV and specific helminth infections.

With its pipeline maturing, DNDi will increasingly focus on access, with the ultimate aim of facilitating maximum impact via appropriate use of treatments, assuring their effective transition to relevant access partners and implementers, and leveraging success for future steps.

A critical component of the updated strategy is the further empowerment of Regional Offices, aiming at their transition from a support role to a more active contribution to all DNDi activities.